Sinopharm Suspends Vaccine Trial in Peru

One of the volunteers has shown symptoms consistent with Guillain-Barré syndrome, which is why clinical trials have been suspended. The trial with the vaccine developed by the Chinese laboratory Sinopharm in Peru to deal with the coronavirus has had to be paralyzed when one of the volunteers presented symptoms compatible with Guillain-Barré syndrome.

The principal investigator of the Cayetano Heredia University, Germán Málaga, informed the institutions that regulate the trial of a participant's appearance "with neurological symptoms compatible with Guillain-Barré syndrome." The 64-year-old affected person also has other previous pathologies.

The National Institute of Health (INS) considers it "unlikely" that the symptoms are related to the antidote's inoculation. But, caution must be shown as in all clinical studies with vaccines, and the INS decided to stop the trials for this reason. To try to clarify the causes, a commission of expert neurologists "is evaluating the medical history process and the tests that are being carried out," according to Malaga.

"There is very little probability that the symptoms have a direct relationship with the vaccine, but when in doubt, it is necessary to be cautious," concluded Málaga.

Peru has reported more than 981,000 coronavirus infections since the start of the pandemic. Besides, 36,544 people have lost their lives due to the disease.

What is Guillain-Barré syndrome?

Guillain-Barré syndrome is a disease characterized by the attack of the immune system on the nerves. Its symptoms first manifest with tingling in the legs and arms, but the paralysis spread throughout the body. Furthermore, weakness, fatigue, and the inability to perform facial movements are other ailments suffered by patients with Guillain-Barré syndrome.

The causes of the disease are unknown, as is its cure. Currently, between 4% and 7% of people with the syndrome die. On the other hand, between 60% and 80% recover after six months.